Literature DB >> 8827356

Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia.

L A Kresty1, S G Carmella, A Borukhova, S A Akerkar, R Gopalakrishnan, R E Harris, G D Stoner, S S Hecht.   

Abstract

Two metabolites of the carcinogenic tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone were quantified in the urine of smokeless tobacco users. The metabolites are 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanol (NNAL) and [4-(methylnitrosamino)-1-(3-pyridyl) but-1-yl]-beta-O-D-glucosiduronic acid (NNAL-Gluc). The study population consisted of 47 male nonsmokers, of whom 23 were snuff dippers, 13 were tobacco chewers, 3 were users of both products, and 8 were nonusers. The levels of NNAL-Gluc in urine ranged from 0.14-30.3 pmol/mg creatinine with a mean +/- SD of 3.47 +/- 5.86, whereas the levels of NNAL ranged from 0.02-8.73 pmol/mg creatinine with a mean +/- SD of 0.92 +/- 1.59. The mean levels of NNAL-Gluc and NNAL were not significantly different from those measured in a previous study of smokers. The levels of NNAL-Gluc were significantly higher in snuff dippers than in tobacco chewers. The ratio of NNAL-Gluc:NNAL was higher in snuff dippers than in tobacco chewers or smokers. There was no indication of two phenotypes of the NNAL-Gluc:NNAL ratio in smokeless tobacco users, in contrast to previous observations in smokers. Of the 39 smokeless tobacco users in this study, 16 presented with oral leukoplakia. When the total levels of NNAL-Gluc, NNAL, or NNAL-Gluc + NNAL were divided into tertiles, there was a significant association between the presence of leukoplakia and increasing levels of these metabolites; a similar relationship was found between urinary cotinine and leukoplakia. The results of this study demonstrate that there is significant uptake of carcinogenic nitrosamines in smokeless tobacco users, and that such products are not harmless alternatives to cigarettes. Moreover, the urinary biomarkers NNAL-Gluc, NNAL, and cotinine were associated with the presence of leukoplakia, which provides biochemical support for the role of smokeless tobacco products as a cause of oral leukoplakia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827356

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Proposed cutoff for identifying adult smokeless tobacco users with urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanonol: an aggregated analysis of NHANES 2007-2010 data.

Authors:  Israel T Agaku; Constantine I Vardavas; Gregory Connolly
Journal:  Nicotine Tob Res       Date:  2013-08-16       Impact factor: 4.244

2.  Comparison of the Carcinogenic Potential of Smokeless Tobacco and Smoked Tobacco by Quantifying the Excretion of Nicotine Metabolite NNAL in Patients with Oral Leukoplakia.

Authors:  S Mohamed Anser; Nalini Aswath
Journal:  Indian J Clin Biochem       Date:  2013-07-23

3.  Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.

Authors:  Binnian Wei; Benjamin C Blount; Baoyun Xia; Lanqing Wang
Journal:  J Expo Sci Environ Epidemiol       Date:  2015-01-07       Impact factor: 5.563

4.  Evidence supporting product standards for carcinogens in smokeless tobacco products.

Authors:  Dorothy K Hatsukami; Irina Stepanov; Herb Severson; Joni A Jensen; Bruce R Lindgren; Kimberly Horn; Samir S Khariwala; Julia Martin; Steven G Carmella; Sharon E Murphy; Stephen S Hecht
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-18

5.  Genetic variability in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).

Authors:  Monica Ter-Minassian; Kofi Asomaning; Yang Zhao; Feng Chen; Li Su; Steven G Carmella; Xihong Lin; Stephen S Hecht; David C Christiani
Journal:  Int J Cancer       Date:  2011-08-03       Impact factor: 7.396

Review 6.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

7.  Identification of more than 100 structurally unique DNA-phosphate adducts formed during rat lung carcinogenesis by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.

Authors:  Bin Ma; Adam T Zarth; Erik S Carlson; Peter W Villalta; Pramod Upadhyaya; Irina Stepanov; Stephen S Hecht
Journal:  Carcinogenesis       Date:  2018-02-09       Impact factor: 4.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.